A Phase 1, Randomized, Placebo controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ACP-014 in Healthy Adult Subjects (ACP-014 -Phase 1)

Trial Profile

A Phase 1, Randomized, Placebo controlled, Single and Multiple Ascending Dose Trial to Evaluate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of ACP-014 in Healthy Adult Subjects (ACP-014 -Phase 1)

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Jul 2018

At a glance

  • Drugs TransCon PTH (Primary)
  • Indications Hypoparathyroidism
  • Focus Adverse reactions; First in man
  • Sponsors Ascendis Pharma Bone Diseases
  • Most Recent Events

    • 30 May 2018 According to the Ascendis Pharma media release, data from the complete multiple ascending dose cohorts were presented at the European Congress of Endocrinology.
    • 30 May 2018 Status changed from recruiting to completed, according to the Ascendis Pharma media release.
    • 07 May 2018 According to an Ascendis Pharma media release, data will be presented at the European Congress of Endocrinology (ECE) 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top